Head-to-head comparison of [ < sup > 68 < /sup >  Ga]Ga-P16-093 and [ < sup > 68 < /sup >  Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients

CONCLUSIONS: [68 Ga]Ga-P16-093 showed advantages over [68 Ga]Ga-PSMA-617 with higher tumor uptakes, tumor-to-blood pool ratio and detection capability, less blood pool, and bladder accumulation in recurrent prostate cancer patients.TRIAL REGISTRATION: [68 Ga]Ga-P16-093 and [68 Ga]Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients (NCT04796467, Registered 12 March 2021, retrospectively registered) URL of registry: https://clinicaltrials.gov/ct2/show/NCT04796467.PMID:34557930 | DOI:10.1007/s00259-021-05539-1

Source: Molecular Medicine - September 24, 2021 Category: Molecular Biology Authors: Guochang Wang Haiyan Hong Jie Zang Qingxing Liu Yuanyuan Jiang Xinrong Fan Zhaohui Zhu Lin Zhu Hank F Kung Source Type: research